Ranking Invest

MORF - Morphic Holding, Inc.

Segmento: HealthcareMorphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; and preclinical trial to treat idiopathic pulmonary fibrosis and fibrosis diseases. The company is also developing avß6 for the treatment of fibrotic diseases, and avß8 to treat solid tumors, as well as various other products. Morphic Holding, Inc. has a research collaboration with Engitix Ltd for the identification of Morphic integrin technology amenable targets in fibrostenotic IBD; a collaboration agreement with Schrödinger, LLC for integrin targets; and a license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. It also has collaboration agreements with AbbVie Biotechnology Ltd and Janssen Pharmaceuticals, Inc. to discover or develop integrin-based therapeutics. Morphic Holding, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

Análise Ranking Invest

Valuation estimado
$ 228.26 Mi
Valor de Mercado
$ 2.86 Bi
Sobrepreço (AV)+1153.9%
MLL
-0.14A companhia gerou lucro líquido equivalente a -14% do seu valor de mercado nos últimos 4 trimestres.
Último Balanço Atualizado: 2T2024

O Ranking Invest utiliza metodologia própria baseada em dados financeiros objetivos, considerando patrimônio, lucratividade e endividamento para estimar o valuation das empresas.

Dados da Empresa

Patrimônio Líquido

$ 618.43 Mi

Dívida Líquida

-$ 47.45 Mi

L4T

-$ 179.83 Mi

MM4T

16.91%

Indicadores Básicos

ROE

-29.08%

Índices de Previsibilidade

Faturamento

2.14

Lucro

0.52

Margem

1.02

Índices de Tendência

Faturamento

-4.80

Lucro

-7.60

Margem

4.08

Índices de Endividamento

DIV/PAT

-0.08

DIV/L4T

0.26

Dívidas
Cotação
Gráfico Lucro/Faturamento X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.